Bristol-Myers names Bancroft as interim CFO, in lieu of Huet's departure

Kaitlyn Dmyterko | | Cardiovascular Business | Structural Heart Disease
Pharmaceutical company Bristol-Myers Squibb has selected Charles Bancroft as its acting CFO, as its current executive vice president and CFO, Jean-Marc Huet, prepares to leave his post at the end of this year.

Effective Jan. 1, 2010, Bancroft, who previously served as vice president of the company, will report to BMS' President and COO Lamberto Andreotti.

According to the New York City-based company, Bancroft joined BMS in 1984 and has held several positions dealing with the organization's finances. 

Kaitlyn Dmyterko

Related Content

Treating younger patients with TAVR increases risk of death
Self-expanding vs. balloon-expandable TAVR valves: How they compare after 5 years
New data put a spotlight on troubling TAVR trends
How robotic-assisted mitral valve repair compares to conventional surgery
Tricuspid TEER shows clinical efficacy for first time in newest TRILUMINATE data
Cardiology societies push Medicare to pay for tricuspid TEER

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Design by Adaptive Theme
Trimed Popup
Trimed Popup